Literature DB >> 35031844

Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity.

Agnès Fernàndez-Clotet1, Víctor Sapena2, Nunzia Capozzi3,4, Sonia Rodríguez3, Maria-Carme Masamunt1,5, Elena Ricart1,6,5,7, Ingrid Ordás1,6,5,7, Julian Panés1,6,5,7, Jordi Rimola8,9.   

Abstract

OBJECTIVES: Patients with Crohn's disease (CD) require multiple assessments with magnetic resonance enterography (MRE) from a young age. Standard MRE protocols for CD include contrast-enhanced sequences. Gadolinium deposits in brain tissue suggest avoiding gadolinium could benefit patients with CD. This study aimed to compare the accuracy of the simplified Magnetic Resonance Index of Activity (sMaRIA) calculated with and without contrast-enhanced sequences in determining the response to biologic drugs in patients with CD.
METHODS: This post hoc analysis of a prospective study included patients with CD with endoscopic ulceration in ≥ 1 intestinal segment starting biologic drug therapy. Two blinded radiologists used the sMaRIA to score images obtained at baseline and week 46 of treatment first using only unenhanced sequences (T2-sMaRIA) and 1 month later using both unenhanced and enhanced images (CE-sMaRIA). We calculated the rates of agreement between T2-sMaRIA, CE-sMaRIA, and ileocolonoscopy for different conceptualizations of therapeutic response.
RESULTS: A total of 46 patients (median age, 36 years [IQR: 28-47]) were included. Agreement with ileocolonoscopy was similar for CE-sMaRIA and T2-sMaRIA in identifying ulcer healing (kappa = 0.74 [0.55-0.93] and 0.70 [0.5-0.9], respectively), treatment response (kappa = 0.53 [0.28-0.79] and 0.44 [0.17 - 0.71]), and remission (kappa = 0.48 [0.22-0.73] and 0.43 [0.17-0.69]). The standardized effect size was moderate for both CE-sMaRIA = 0.63 [0.41-0.85] p < 0.001 and T2-sMaRIA = 0.58 [0.36-0.80] p < 0.001.
CONCLUSIONS: sMaRIA with and without contrast-enhanced images accurately classified the response according to different therapeutic endpoints determined by ileocolonoscopy. KEY POINTS: • The simplified Magnetic Resonance Index of Activity is accurate for the assessment of Crohn's disease activity, severity, and therapeutic response, using four dichotomic components that can be evaluated without the need of using contrast-enhanced sequences, representing a practical and safety advantage, but concerns have been expressed as to whether the lack of contrast sequences may compromise precision. • The simplified Magnetic Resonance Index of Activity can assess the response to biologic therapy in patients with Crohn's disease without the need for intravenous contrast agents obtaining comparable results without and with contrast-enhanced sequences. • Avoiding intravenous contrast agents could reduce the duration of the MRE examination and its cost and would increase the acceptance and safety of MRE in clinical research in patients with Crohn's disease.
© 2021. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Crohn’s disease; Gadolinium; Magnetic resonance enterography; Simplified MaRIA; Therapeutic response

Mesh:

Substances:

Year:  2022        PMID: 35031844     DOI: 10.1007/s00330-021-08392-w

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  22 in total

1.  Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.

Authors:  Ingrid Ordás; Jordi Rimola; Sonia Rodríguez; José M Paredes; María J Martínez-Pérez; Esther Blanc; Juan A Arévalo; Marta Aduna; Montserrat Andreu; Alexander Radosevic; Anna M Ramírez-Morros; Susana Pinó; Marta Gallego; Aranzazu Jauregui-Amezaga; Elena Ricart; Julián Panés
Journal:  Gastroenterology       Date:  2013-10-29       Impact factor: 22.682

2.  Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography.

Authors:  Vipul Jairath; Ingrid Ordas; Guangyong Zou; Julian Panes; Jaap Stoker; Stuart A Taylor; Cynthia Santillan; Karin Horsthuis; Mark A Samaan; Lisa M Shackelton; Larry W Stitt; Pieter Hindryckx; Reena Khanna; William J Sandborn; Geert D'Haens; Brian G Feagan; Barrett G Levesque; Jordi Rimola
Journal:  Inflamm Bowel Dis       Date:  2018-01-18       Impact factor: 5.325

3.  Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design.

Authors:  Maria T Abreu; William J Sandborn
Journal:  Gastroenterology       Date:  2020-09-19       Impact factor: 22.682

4.  Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease.

Authors:  Jordi Rimola; Agnès Fernàndez-Clotet; Nunzia Capozzi; Sònia Rojas-Farreras; Ignacio Alfaro; Sonia Rodríguez; Maria-Carme Masamunt; Elena Ricart; Ingrid Ordás; Julian Panés
Journal:  Aliment Pharmacol Ther       Date:  2020-09-04       Impact factor: 8.171

Review 5.  Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease.

Authors:  David H Bruining; Ellen M Zimmermann; Edward V Loftus; William J Sandborn; Cary G Sauer; Scott A Strong
Journal:  Gastroenterology       Date:  2018-01-10       Impact factor: 22.682

6.  Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.

Authors:  Silvio Danese; William J Sandborn; Jean-Frédéric Colombel; Séverine Vermeire; Sarah C Glover; Jordi Rimola; Jenifer Siegelman; Stephen Jones; Jeffrey D Bornstein; Brian G Feagan
Journal:  Gastroenterology       Date:  2019-07-04       Impact factor: 22.682

7.  Development and Validation of a Simplified Magnetic Resonance Index of Activity for Crohn's Disease.

Authors:  Ingrid Ordás; Jordi Rimola; Ignacio Alfaro; Sonia Rodríguez; Jesús Castro-Poceiro; Anna Ramírez-Morros; Marta Gallego; Àngel Giner; Rebeca Barastegui; Agnès Fernández-Clotet; Maica Masamunt; Elena Ricart; Julián Panés
Journal:  Gastroenterology       Date:  2019-04-03       Impact factor: 22.682

8.  Value of endoscopy and MRI for predicting intestinal surgery in patients with Crohn's disease in the era of biologics.

Authors:  A Jauregui-Amezaga; J Rimola; I Ordás; S Rodríguez; A Ramírez-Morros; M Gallego; M C Masamunt; J Llach; B González-Suárez; E Ricart; J Panés
Journal:  Gut       Date:  2014-12-16       Impact factor: 23.059

Review 9.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

10.  The Tight Junction Protein ZO-1 Is Dispensable for Barrier Function but Critical for Effective Mucosal Repair.

Authors:  Wei-Ting Kuo; Li Zuo; Matthew A Odenwald; Shariq Madha; Gurminder Singh; Christine B Gurniak; Clara Abraham; Jerrold R Turner
Journal:  Gastroenterology       Date:  2021-08-31       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.